Research programme: interleukin-2 mimetic peptide - AplaGenAlternative Names: AGIL2-03; Research programme: IL2 mimetic peptide - AplaGen
Latest Information Update: 30 Jan 2007
At a glance
- Originator AplaGen
- Mechanism of Action Interleukin 2 stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 30 Jan 2007 This programme is still in active development for cancer in Germany
- 30 Nov 2005 Preclinical trials in Cancer in Germany (unspecified route)